Intranasal administration of active agents to the central nervous system -> Monitor Keywords
Fresh Patents
Monitor Patents Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations
site info Site News  |  monitor Monitor Keywords  |  monitor archive Monitor Archive  |  organizer Organizer  |  account info Account Info  |  
05/28/09 - USPTO Class 424 |  views | #20090136505 | Prev - Next | About this Page  424 rss/xml feed  monitor keywords

Intranasal administration of active agents to the central nervous system

USPTO Application #: 20090136505
Title: Intranasal administration of active agents to the central nervous system
Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents. (end of abstract)



Agent: Philip S. Johnson Johnson & Johnson - New Brunswick, NJ, US
Inventors: Johanna Bentz, Beth Hill, Lisbeth Illum
USPTO Applicaton #: 20090136505 - Class: 4241391 (USPTO)

Intranasal administration of active agents to the central nervous system description/claims


The Patent Description & Claims data below is from USPTO Patent Application 20090136505, Intranasal administration of active agents to the central nervous system.

Brief Patent Description - Full Patent Description - Patent Application Claims
  monitor keywords US20090136505A1-20090528.XML CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/655,809, filed Feb. 23, 2005 and U.S. Utility application Ser. No. 11/342,058 filed Jan. 1, 2006, both of which are incorporated herein by reference in their entirety.

TECHNICAL FIELD

The subject matter described herein relates to methods and compositions for intranasal administration of active agents to the central nervous system of a mammal.

BACKGROUND

Delivery of drugs to the central nervous system (CNS) remains a challenge, despite recent advances in drug delivery and knowledge of mechanisms of delivery of drugs to the brain. For example, CNS targets are poorly accessible from the peripheral circulation due to the blood-brain barrier (BBB), which provides an efficient barrier for the diffusion of most, especially polar, drugs into the brain from the circulating blood. Attempts to circumvent the problems associated with the BBB to deliver drugs to the CNS include: 1) design of lipophilic molecules, as lipid soluble drugs with a molecular weight of less than 600 Da readily diffuse through the barrier; 2) binding of drugs to transporter molecules which cross the BBB via a saturable transporter system, such as transferrin, insulin, IGF-1, and leptin; and 3) binding of drugs to polycationic molecules such as positively-charged proteins that preferentially bind to the negatively-charged endothelial surface (See, e.g., Illum, Eur. J. Pharm. Sci. 11:1-18 (2000) and references therein; W. M. Partridge. “Blood-brain barrier drug targeting: the future of brain drug development”, Mol. Interv. 3(2):90-105 (2003); W. M. Partridge et al., “Drug and gene targeting to the Brain with molecular Trojan horses”, Nature Reviews-Drug Discovery 1:131-139 (2002)).

The intranasal route has been explored as a non-invasive method to circumvent the BBB for transport of drugs to the CNS. Although intranasal delivery to the CNS has been demonstrated for a number of small molecules and some peptides and smaller proteins, there is little evidence demonstrating the delivery of protein macromolecules to the CNS via intranasal pathways, presumably due to the larger size and varying physico-chemical properties unique to each macromolecule or class of macromolecules, that may hinder direct nose-to-brain delivery.

The primary physical barrier for intranasal delivery is the respiratory and olfactory epithelia of the nose. It has been shown that the permeability of the epithelial tight junctions in the body is variable and is typically limited to molecules with a hydrodynamic radius less than 3.6 A; permeability is thought to be negligible for globular molecules with a radius larger than 15 A (B. R. Stevenson et al., Mol. Cell. Biochem. 83, 129-145 (1988)). Therefore, the size of the molecule to be administered is considered an important factor in achieving intranasal transport of a macromolecule to the central nervous system. Fluorescein-labeled dextran, a linear molecule having a dextran molecular weight of 20 kD can be delivered to cerebrospinal fluid from the rat nasal cavity, however 40 kDa dextran cannot (Sakane et al, J. Pharm. Pharmacol. 47, 379-381 (1995)). It has also been reported that an infectious organism, such as a virus, can enter the brain through the olfactory region of the nose (S. Perlman et al., Adv. Exp. Med. Biol, 380:73-78 (1995)).

In published delivery studies to date, intranasal delivery efficiency to the CNS has been very low and the delivery of large globular macromolecules, such as antibodies and their fragments, has not been demonstrated. Yet, because antibodies, antibody fragments, and antibody fusion molecules are potentially useful therapies for treating disorders having a CNS target, e.g., Alzheimer\'s disease, Parkinson\'s disease, multiple sclerosis, stroke, epilepsy, and metabolic and endocrine disorders, it is desirable to provide a method for delivering these large macromolecules to the CNS non-invasively.

BRIEF SUMMARY

An aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc or Fab fragment; and a permeation enhancer in a concentration sufficient to enhance intranasal administration of the catalytically active peptide chain or peptide chain comprising an antibody Fc or Fab fragment to the central nervous system of an animal.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc or Fab fragment; and about 0.1 to about 1 g of chitosan glutamate per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc fragment; and from about 0.125 g to about 1 g of a compound selected from the group consisting of 1-O-n-dodecyl-beta-D-maltopyranoside, 1-O-n-decyl-beta-D-maltopyranoside, 1-O-n-tetradecyl-beta-D-maltopyranoside, and beta-D-fructopyranosyl-alpha-glucopyranoside monododecanoate per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc fragment; and from about 5 ml to about 20 ml of propylene glycol per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state and the propylene glycol is at standard state.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc fragment; and about 5 g of heptakis (2,6-di-O-methyl)-beta-cyclodextrin per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc fragment; and about 2 g of 1,2-didecanoyl-sn-glycero-3-phosphocholine per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state and the 1,2-didecanoyl-sn-glycero-3-phosphocholine is emulsified in the aqueous buffer.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc fragment; and about 0.1 to about 1 g of a compound selected from the group consisting of sodium glycocholate hydrate, taurocholic acid sodium salt hydrate, and sodium tauroursodeoxycholate per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state.

Another aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc fragment; and from about 1 ml to about 10 ml of tetrahydrofurfuryl polyethylenglycol per 100 ml of the pharmaceutical composition; wherein the diluent is an aqueous buffer at standard state and the tetrahydrofurfuryl-polyethylenglycol is at standard state.

These and other aspects and embodiments will be apparent from the description, drawings, and sequences herein.



Continue reading about Intranasal administration of active agents to the central nervous system...
Full patent description for Intranasal administration of active agents to the central nervous system

Brief Patent Description - Full Patent Description - Patent Application Claims

Click on the above for other options relating to this Intranasal administration of active agents to the central nervous system patent application.

Patent Applications in related categories:

20100021466 - Antagonistic human light-specific human monoclonal antibodies - Provided herein are antibodies, such as fully human antibodies that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as ...

20100021463 - Antibodies to ip-10 for treating bone diseases with bone destruction - The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating ...

20100021465 - Boris isoforms and methods of detecting and treating disease - A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a ...

20100021469 - Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology - The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present ...

20100021467 - Method of detecting a cancer cell by aberrant expression of a human k+ ion channel - The present invention relates to a novel human K+ ion channel, to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to antibodies specifically directed to the novel K+ ion channel and to pharmaceutical compositions and diagnostic kits containing at least ...

20100021464 - Methods of wound care and treatment - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface ...

20100021468 - Novel mhc class ii restricted t cell epitopes from the cancer anitgen, ny eso-1 - The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products ...


###
monitor keywords

Other recent patent applications listed under the agent Philip S. Johnson Johnson & Johnson:

20090320408 - Method and device for forming pre-made pouches
20090321970 - Ophthalmic lens molds parts with siloxane wax
20090322630 - Blood glucose level measurement and wireless transmission unit
20090324523 - Compositions comprising an ultraviolet radiation-absorbing polymer
20090324524 - Compositions comprising an ultraviolet radiation-absorbing polymer
20090324539 - Cancer treatment combining lymphodepleting agent with ctls and cytokines
20090324664 - Spray-on, non-woven fabric system and multilayer topical covering
20090324691 - Methods and ophthalmic devices used in the treatment of ocular allergies
20090324713 - Spray-on, non-woven fabric system and multilayer wound coverings
20090324716 - Coated particles containing pharmaceutically active agents
20090325188 - Method for detecting il-16 activity and modulation of il-16 activity based on rantes proxy levels
20090325287 - Methods for obtaining high viable cell density in mammalian cell culture
20090325293 - Treatment of pluripotent cells
20090325294 - Single pluripotent stem cell culture
20090325307 - Method for manufacturing a strip for use with a multi-input meter
20090325873 - Human glp-1 mimetibodies, compositions, methods and uses
20090325927 - Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
20090325963 - Iontophoretic delivery of curcumin and curcumin analogs for the treatment of alzheimer's disease
20090325980 - Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds
20090326035 - Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
20090326095 - Viscous alpha-cyanoacrylate compositions
20090326182 - Compositions comprising an ultraviolet radiation-absorbing polymer
20090326258 - Process for the preparation of substituted tetralin and substituted indane derivatives
20090326275 - Use of nitrogen-containing curcumin analogs for the treatment of alzheimers disease
20090326433 - Implantable device for the treatment of obesity
20090326457 - Volumetric micropump
20090326459 - Drive mechanism and method of use
20090326517 - Fluidic capillary chip for regulating drug flow rates of infusion pumps
20090326519 - Multiple lumen sensor attachment
20090326583 - Posterior dynamic stabilization system with flexible ligament
20090326584 - Spinal dynamic stabilization rods having interior bumpers
20090326657 - Pliable artificial disc endplate
20090326675 - Implantable device for the treatment of obesity
20090326722 - Method and system for using status indicators in wireless communication with medical devices
20090314425 - Method of manufacturing analyte test strip for accepting diverse sample volumes
20090317297 - Analyte test strip for accepting diverse sample volumes
20090317339 - Teeth bleaching compositions and devices
20090317485 - Skin protectant spray compositions
20090317847 - Method for determining an analtye in a bodily fluid
20090318332 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
20090318343 - Protein formulations for use at elevated temperatures
20090318498 - Piperidyl acrylamide antagonists of ccr2
20090318544 - Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
20090318793 - Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
20090318796 - Patch and sensor assembly for use in medical device localization and mapping systems
20090318829 - Sample collection and testing device with pivot arm
20090318955 - Vascular closure device
20090308907 - Partially reusable surgical stapler
20090308909 - Partially reusable surgical stapler
20090311299 - Antithrombotic coating for drug eluting medical devices
20090311344 - Dosing regimen
20090311734 - Laser illumination system in fluorescent microscopy
20090312399 - Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells
20090312284 - Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
20090312339 - Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
20090312412 - 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers
20090312578 - Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
20090312720 - Post laser drilling stress relief of surgical needles made of refractory alloys
20090312744 - Pulsatile flux drug delivery
20090312748 - Rotational detachment mechanism
20090302872 - Electrochemical strip for use with a multi-input meter
20090302873 - System for electrochemically measuring an analyte in a sample material
20090305418 - Cell therapy method for the treatment of tumors
20090305430 - Device for preparing bone cement
20090306118 - Trisubstituted thiophenes as progesterone receptor modulators
20090306349 - Binding partners with immunoglobulin domains modified to have extended half-life
20090306392 - Gsm intermediates
20090306608 - Ophthalmic devices for the controlled release of active agents
20090306641 - Filter for simultaneous pacing and ablation
20090306650 - Catheter with bendable tip
20090306666 - Intramedullary nail with oblique openings
20090306674 - Device for preparing bone cement
20090306785 - Knee joint prosthesis
20090294695 - Sample plate designs for maldi and desi for molecular imaging of coated medical devices on the applied biosystems qstar/voyager maldi mass spectrometer
20090295004 - Silicone hydrogel contact lenses displaying reduced protein uptake
20090295683 - Head mounted display with variable focal length lens
20090297469 - Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone and 2,4,4'-trichloro-2'-hydroxydiphenyl ether
20090297502 - Ccr2 antagonists for chronic organ transplantation rejection
20090298052 - Diagnosing or predicting the course of breast cancer
20090298186 - Method to assess stability of proteins
20090298867 - Tricyclic delta-opioid modulators
20090298874 - Bacterial atp synthase binding domain
20090299034 - Collagen-related peptides
20090299161 - Marker of wound infection
20090299407 - Methods for using looped tissue-grasping devices
20090299408 - Surgical thread and surgical implant with the same
20090299451 - Device for loading self-expanding stents


How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Intranasal administration of active agents to the central nervous system or other areas of interest.
###


Previous Patent Application:
Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
Next Patent Application:
Method of diagnosing colon and gastric cancers
Industry Class:
Drug, bio-affecting and body treating compositions

###

FreshPatents.com Support
Thank you for viewing the Intranasal administration of active agents to the central nervous system patent info.
IP-related news and info


Results in 2.50936 seconds


Other interesting Feshpatents.com categories:
Electronics: Semiconductor Audio Illumination Connectors Crypto paws
PATENT INFO